Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;145(3):600-606.
doi: 10.1017/S0950268816002624. Epub 2016 Nov 22.

Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis

Affiliations

Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis

R H V Pereira et al. Epidemiol Infect. 2017 Feb.

Abstract

Achromobacter spp. are opportunistic pathogens increasingly recovered from adult patients with cystic fibrosis (CF). We report the characterization of 122 Achromobacter spp. isolates recovered from 39 CF patients by multilocus sequence typing, virulence traits, and susceptibility to antimicrobials. Two species, A. xylosoxidans (77%) and A. ruhlandii (23%) were identified. All isolates showed a similar biofilm formation ability, and a positive swimming phenotype. By contrast, 4·3% and 44·4% of A. xylosoxidans and A. ruhlandii, respectively, exhibited a negative swarming phenotype, making the swimming and swarming abilities of A. xylosoxidans significantly higher than those of A. ruhlandii. A. xylosoxidans isolates from an outbreak clone also exhibited significantly higher motility. Both species were generally susceptible to ceftazidime, ciprofloxacin, imipenem and trimethoprim/sulphamethoxazole and there was no significant difference in susceptibility between isolates from chronic or sporadic infection. However, A. xylosoxidans isolates from chronic and sporadic cases were significantly more resistant to imipenem and ceftazidime than isolates of the outbreak clone.

Keywords: Achromobacter; clinical microbiology; cystic fibrosis.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1.
Fig. 1.
(a) Swimming and (b) swarming motility of Achromobacter xylosoxidans and A. ruhlandii. (c) Swimming and (d) swarming motility of A. xylosoxidans isolates of the outbreak clone and patients with chronic or sporadic infection. Data are medians, and bars represent the interquartile range. * P < 0·05, *** P < 0·001.

References

    1. Ciofu O, Hansen CR, Høiby N. Respiratory bacterial infections in cystic fibrosis. Current Opinion in Pulmonary Medicine 2013; 19: 251–258. - PubMed
    1. Tan K, et al. Alcaligenes infection in cystic fibrosis. Pediatric Pulmonology 2002; 34: 101–104. - PubMed
    1. De Baets F, et al. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. Journal of Cystic Fibrosis 2007; 6: 75–78. - PubMed
    1. Ronne-Hansen CR, et al. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. Journal of Cystic Fibrosis 2006; 5: 245–251. - PubMed
    1. Ronne-Hansen CR, et al. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. Journal of Cystic Fibrosis 2010; 9: 51–58. - PubMed

Publication types

MeSH terms